Key result
Aspirin use is linked to lower aortic valve calcification and stenosis risk specifically with high Lp(a).
Why the study?
Lipoprotein(a) and LDL cholesterol are causally linked to aortic valve calcium and stenosis, and aspirin may reduce cardiovascular risk among individuals with high Lp(a).
Does regular aspirin use reduce incident aortic valve calcium and severe aortic stenosis in individuals with elevated Lp(a)?
Observational (n=6,598)
Yes
Does regular aspirin use reduce incident aortic valve calcium and severe aortic stenosis in individuals with elevated Lp(a)?
Answers are grounded in this paper and cite their sources.
Regular aspirin use is associated with a significantly lower risk of incident aortic valve calcium and severe aortic stenosis specifically in individuals with elevated Lp(a).
BACKGROUND AND AIMS: Lipoprotein(a) [Lp(a)] and LDL cholesterol (LDL-C) are causally linked to aortic valve calcium (AVC) and aortic stenosis (AS). Lipoprotein(a) has anti-fibrinolytic properties; therefore, aspirin may reduce cardiovascular disease risk among individuals with high Lp(a). This analysis sought to determine the association of aspirin with incident AVC and AS across Lp(a) and LDL-C levels. METHODS: This observational study included up to 6598 participants in the Multi-Ethnic Study of Atherosclerosis. Aortic valve calcium was measured on non-contrast cardiac computed tomography. Multivariable Cox hazards regression assessed the association of self-reported regular aspirin use (≥3 days/week) with incident AVC and severe AS, stratified by Lp(a) and LDL-C. Aortic valve calcium and Lp(a) values were not reported to participants. RESULTS: Mean age was 62 years, 53% were women, 23% reported regular aspirin use, 8% developed AVC (median 8.9 years), and 1% developed severe AS (median 16.7 years). Among individuals with elevated Lp(a), regular aspirin use was associated with a lower risk of incident AVC (Lp(a) ≥75 mg/dL: hazard ratio (HR) .42, 95% confidence interval (CI) .19-.93; Lp(a) ≥100 mg/dL: HR .17, 95% CI .04-.67) and severe AS (Lp(a) ≥50 mg/dL: HR .13, 95% CI: .04-.47; Lp(a) ≥75 mg/dL: HR .02, 95% CI .001-.29). For participants with elevated LDL-C, there was no association of regular aspirin use with incident AVC (LDL-C ≥130 mg/dL: HR 1.02, 95% CI .66-1.58; LDL-C ≥160 mg/dL: HR 1.51, 95% CI .53-4.28) or severe AS (LDL-C ≥100 mg/dL: HR .70, 95% CI .39-1.26; LDL-C ≥130 mg/dL: HR .46, 95% CI .14-1.47). CONCLUSIONS: In this exploratory analysis of prospective observational cohort data, regular aspirin use was associated with a lower risk of AVC and severe AS in persons with high Lp(a), but not high LDL-C. Confirmatory studies are required to determine the role of aspirin in the prevention of AVC and AS for persons with high Lp(a).
No takes yet. Share an insight, caveat, or question.
Razavi et al. (2026) conducted an observational in Calcific aortic valve disease (n=6,598). Regular aspirin use vs. No regular aspirin use was evaluated on Incident aortic valve calcium in individuals with Lp(a) ≥75 mg/dL (HR 0.42, 95% CI 0.19-0.93). Regular aspirin use was associated with a lower risk of incident aortic valve calcium and severe aortic stenosis in persons with high Lp(a), but not high LDL-C.
Synapse has enriched 10 related papers. Consider them for comparative context: